Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437850 | 0.89 | NPC1 (0.43) | SMN1; SMN2TDP1NPC1RAB9AKDM4E | |
| SCHEMBL2813073 | 0.89 | IL2 (0.47) | SMN1; SMN2TDP1NPC1RAB9AALDH1A1 | |
| SCHEMBL438987 | 0.87 | L3MBTL1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1RXFP1 | |
| SCHEMBL438956 | 0.85 | STIM1 (0.50) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL449981 | 0.83 | IL2 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1ABL1 | |
| SCHEMBL2815050 | 0.82 | ABCB1 (0.42) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL6110099 | 0.78 | STIM1 (0.51) | ABL1 | |
| SCHEMBL440417 | 0.78 | NAMPT (0.43) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL450945 | 0.78 | STIM1 (0.61) | VCPTRPM4 | |
| SCHEMBL12155410 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2TDP1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | claimed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | claimed |
| US-8642720-B2 | Photoelectric conversion element, method of manufacturing photoelectric conversion element and solar cell | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120060927-A1 | PHOTOELECTRIC CONVERSION ELEMENT, METHOD OF MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR3, TSLP | SMN1; SMN2 4808/4885TDP1 3352/4885NPC1 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.